Xbrane Biopharma AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0007789409
SEK
9.75
0.85 (9.49%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Xbrane Biopharma AB stock-summary
stock-summary
Xbrane Biopharma AB
Pharmaceuticals & Biotechnology
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Company Coordinates stock-summary
Company Details
Banvaktsvagen 22 , SOLNA None : 171 48
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Anders Tullgren
Independent Chairman of the Board
Mr. Giorgio Chirivi
Independent Director
Mr. Ivan Cohen-Tangui
Independent Director
Prof. Peter Edman
Independent Director
Ms. Eva Nilsagard
Independent Director
Ms. Karin Wingstrand
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
40 Million
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 208 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.16

stock-summary
Return on Equity

-12.41%

stock-summary
Price to Book

0.35